Literature DB >> 33417056

Operating on Jehovah's Witnesses: A Challenging Surgical Issue.

Zoe Garoufalia1,2, Apostolos Aggelis3, Efstathios A Antoniou3, Gregory Kouraklis3, Costantine Vagianos3.   

Abstract

Blood transfusion is often utilized in surgery. Greece is the second-highest consumer of blood components in Europe. It has been shown that at least half of all transfusions are unnecessary and could be avoided. Jehovah's Witnesses (JWs) are a Christian religion that do not accept transfusion of whole blood or the four primary components of blood-namely, red blood cells, white blood cells, platelets, and plasma. This a retrospective study from September of 2015 to January of 2018, analyzing all JWs who underwent an elective operation at the Second Department of Propaedeutic Surgery in Laiko University Hospital. Twenty-nine (Rogers et al. in NCCN Guidelines Version 2.2014 Cancer- and Chemotherapy-Induced Anemia. NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network, Fort Washington, 2013) JW patients, 23 females (74.1%) and eight males, were operated on during the aforementioned period. The median ASA score was 1 (range 1-3), and only two of the patients needed postoperative monitoring in the ICU. Almost half of the patients (45.1%) needed iron infusion and EPO injection preoperatively. Two patients presented with postoperative complications, with no postoperative deaths. In conclusion, we found that surgery, in our small group of JW patients, was safe and successful despite the lack of blood transfusion. Techniques developed to treat JW patients should be more widely used to improve clinical outcomes and reduce costs to the healthcare system.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  Blood; Blood products; General surgery; Jehovah’s; Transfusion

Mesh:

Year:  2021        PMID: 33417056     DOI: 10.1007/s10943-020-01175-5

Source DB:  PubMed          Journal:  J Relig Health        ISSN: 0022-4197


  33 in total

1.  A 44-year-old Jehovah's Witness with life-threatening anemia from uterine bleeding.

Authors:  Bassam Hashem; Thomas A Dillard
Journal:  Chest       Date:  2004-03       Impact factor: 9.410

2.  Optimization of tissue oxygenation in critically ill Jehovah's Witness patients.

Authors:  Peter V Dicpinigaitis
Journal:  Am J Med       Date:  2010-08       Impact factor: 4.965

3.  Perioperative Management of a Jehovah's Witness Presenting for Skull Base Surgery.

Authors:  M A Chaney; W S Jellish; J P Leonetti
Journal:  Skull Base Surg       Date:  1996

Review 4.  A comprehensive review of topical hemostatic agents: efficacy and recommendations for use.

Authors:  Hardean E Achneck; Bantayehu Sileshi; Ryan M Jamiolkowski; David M Albala; Mark L Shapiro; Jeffrey H Lawson
Journal:  Ann Surg       Date:  2010-02       Impact factor: 12.969

Review 5.  Red blood cell transfusion policy: a critical literature review.

Authors:  Massimo Franchini; Giuseppe Marano; Carlo Mengoli; Simonetta Pupella; Stefania Vaglio; Manuel Muñoz; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2017-07       Impact factor: 3.443

6.  Transfusion of Red Blood Cells.

Authors:  Jason Alexander; Adam S Cifu
Journal:  JAMA       Date:  2016-11-15       Impact factor: 56.272

7.  Restrictive blood transfusion practices are associated with improved patient outcomes.

Authors:  Lawrence T Goodnough; Paul Maggio; Eric Hadhazy; Lisa Shieh; Tina Hernandez-Boussard; Paul Khari; Neil Shah
Journal:  Transfusion       Date:  2014-07-04       Impact factor: 3.157

8.  Surgical outcomes and transfusion of minimal amounts of blood in the operating room.

Authors:  Victor A Ferraris; Daniel L Davenport; Sibu P Saha; Peter C Austin; Joseph B Zwischenberger
Journal:  Arch Surg       Date:  2012-01

9.  Jehovah's Witnesses. The surgical/ethical challenge.

Authors:  J L Dixon; M G Smalley
Journal:  JAMA       Date:  1981-11-27       Impact factor: 56.272

10.  Risk-adjusted clinical outcomes in patients enrolled in a bloodless program.

Authors:  Steven M Frank; Elizabeth C Wick; Amy E Dezern; Paul M Ness; Jack O Wasey; Andrew C Pippa; Elizabeth Dackiw; Linda M S Resar
Journal:  Transfusion       Date:  2014-06-18       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.